Drugs / ZM008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06451497 | May 2024 → Dec 2026 expected | biliary tract cancer, colorectal cancer, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma +7 | Zumutor Biologics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-08-11 | Zumutor Biologics Inc. | Regulatory Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers zumutor.com ↗
today announces that the US Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers. |
| 2022-07-05 | Zumutor Biologics Inc. | Regulatory Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application zumutor.com ↗
We appreciate the FDA’s thoughtful guidance on the proposed chemistry, manufacturing and control (CMC), nonclinical and clinical development program of our novel monoclonal antibody ZM008. |
| 2022-07-05 | Zumutor Biologics Inc. | Results Abrogation of natural killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers. zumutor.com ↗
Results: TCGA analysis revealed differential LLT1 gene expression in advance stages of NSCLC, TNBC, HNSCC, PRAD and urothelial cancers and high correlation with immune checkpoint pathways. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-23 | Coherus Oncology, Inc. | Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) coherus.com ↗ |
| 2023-08-11 | Zumutor Biologics Inc. | Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers zumutor.com ↗ |
| 2023-02-16 | Zumutor Biologics Inc. | Zumutor receives the US patent for its novel biologic ZM008 zumutor.com ↗ |
| 2022-07-05 | Zumutor Biologics Inc. | Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application zumutor.com ↗ |
| 2022-07-05 | Zumutor Biologics Inc. | Abrogation of natural killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers. zumutor.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZM008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06451497 ↗ |
| Route | Intravenous | “Intravenous delivery” NCT06451497 ↗ |